[1]梁超,李浩,韩大千,等.支气管动脉灌注化疗栓塞联合替雷利珠单抗治疗晚期非小细胞肺癌的有效性与安全性[J].介入放射学杂志,2025,34(02):148-153.
　LIANG Chao,LI Hao,HAN Daqian,et al.Efficacy and safety of bronchial arterial chemoembolization combined with tislelizumab for advanced non-small cell lung cancer [J].journal interventional radiology,2025,34(02):148-153.
点击复制

支气管动脉灌注化疗栓塞联合替雷利珠单抗治疗晚期非小细胞肺癌的有效性与安全性()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年02
页码:
148-153
栏目:
肿瘤介入
出版日期:
2025-02-17

文章信息/Info

Title:
Efficacy and safety of bronchial arterial chemoembolization combined with tislelizumab for advanced non-small cell lung cancer
作者:
梁超; 李浩; 韩大千; 王嘉铖; 许文泽; 王满周; 邝东林; 任建庄; 韩新巍; 段旭华
Author(s):
LIANG Chao; LI Hao; HAN Daqian; WANG Jiacheng; XU Wenze; WANG Manzhou; KUANG Donglin; REN Jianzhuang; HAN Xinwei; DUAN Xuhua.
Department of Interventional Radiology，First Affiliated Hospital of Zhengzhou University，Zhengzhou，Henan Province 450052，China
关键词:
【关键词】非小细胞肺癌; PD-1; 替雷利珠单抗; 支气管动脉化疗栓塞
文献标志码:
A
摘要:
【摘要】目的评估支气管动脉化疗栓塞（BACE）联合替雷利珠单抗治疗晚期非小细胞肺癌（NSCLC）的有效性和安全性。方法纳入郑州大学第一附属医院2021年12月至2022年8月Ⅲ-Ⅳ期NSCLC患者30例。BACE治疗后，每3周应用替雷利珠单抗200 mg治疗1次，直到疾病进展、出现无法耐受的不良反应或研究者决定终止该药物。以无进展生存期（PFS）为主要研究终点，以总生存期（OS）、客观反应率（ORR）、疾病控制率（DCR）、安全性和生活质量（QoL）为次要研究终点。结果中位随访时间为12个月（1.5~12个月）。中位PFS为10.5个月（95%CI：7.8~13.2），未达到中位OS。3、6和12个月的ORR分别为63.3%（95%CI：43.9%~80.1%）、56.7%（95%CI：37.4%~74.5%）和30.4%（95%CI：13.2%~52.9%），DCR分别为 80%（95%CI：61.4%~92.3%）、76.7%（95%CI：57.7%~90.1%）、47.8%（95%CI：26.8%~69.4%）。PD-L1表达≥50%（HR=0.29，P=0.039）、单一肿瘤供血动脉（HR=0.35，P=0.028）、完成超过10个周期的替雷利珠单抗治疗（HR=0.42，P=0.064）是影响PFS的保护因素。未发生3级或以上治疗相关不良事件，常见的2级以下不良反应为恶心、发热和咳嗽。与基线相比，治疗1个周期后患者的生活质量明显改善，包括整体生活质量、身体功能和情绪功能。结论BACE联合替雷利珠单抗对晚期NSCLC患者具有良好的疗效与安全性。

参考文献/References:

［1］Cao W，Chen HD，Yu YW，et al.Changing profiles of cancer burden worldwide and in China：a secondary analysis of the global cancer statistics 2020［J］.Chin Med J （Engl），2021，134：783-791.
［2］中国抗癌协会肿瘤介入学专业委员会.支气管动脉灌注术和支气管动脉化疗栓塞术治疗肺癌的中国专家共识（2023版）［J］.介入放射学杂志，2024，33：219-229.
［3］Guo H，Zhang J，Qin C，et al.Biomarker-targeted therapies in non-small cell lung cancer：current status and perspectives［J］.Cells，2022，11：3200.
［4］Gridelli C，Rossi A，Carbone DP，et al.Non-small-cell lung cancer［J］.Nat Rev Dis Primers，2015，1：15009.
［5］Chen C，Wang W，Yu Z，et al.Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage Ⅲ non-small cell lung cancer after failure of concurrent chemoradiotherapy［J］.Lung Cancer，2020，146：290-296.
［6］Kunisada K，Ishikawa H，Takafuji J，et al.A case of a 91-year-old patient with advanced squamous cell lung cancer complicated with renal dysfunction successfully treated with trans-arterial chemo-embolization［J］.Gan To Kagaku Ryoho，2013，40：917-919.
［7］He X，Du Y，Wang Z，et al.Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma［J］.J Immunother Cancer，2020，8：e000807.
［8］Xu S，Li YM，Bie ZX，et al.Drug-eluting beads bronchial arterial chemoembolization/bronchial arterial infusion chemotherapy with and without PD-1 blockade for advanced non-small cell lung cancer：a comparative single-center cohort study［J］.Quant Imaging Med Surg，2023，13：6241-6256.
［9］Li YM，Guo RQ，Bie ZX，et al.Sintilimab plus bronchial arterial infusion chemotherapy/drug-eluting embolic chemoembolization for advanced non-small cell lung cancer：a preliminary study of 10 patients［J］.J Vasc Interv Radiol，2021，32：1679-1687.
［10］Xu S，Bie Z，Li Y，et al.Drug-eluting bead bronchial arterial chemoembolization with and without microwave ablation for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer：a comparative study［J］.Front Oncol，2022，12：851830.
［11］Zhang T，Song X，Xu L，et al.The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions［J］.Cancer Immunol Immunother，2018，67：1079-1090.
［12］Desai J，Deva S，Lee JS，et al.Phase IA/IB study of single-agent tislelizumab，an investigational anti-PD-1 antibody，in solid tumors［J］.J Immunother Cancer，2020，8：e000453.
［13］Shen L，Guo J，Zhang Q，et al.Tislelizumab in Chinese patients with advanced solid tumors：an open-label，non-comparative，phase 1/2 study［J］.J Immunother Cancer，2020，8：e000437.
［14］Lu S，Wang J，Yu Y，et al.Tislelizumab plus chemotherapy as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC （RATIONALE 304）：a randomized phase 3 trial［J］.J Thorac Oncol，2021，16：1512-1522.
［15］Detterbeck FC,Boffa DJ,Kim AW,et al.The Eighth Edition Lung Cancer Stage Classification［J］.Chest,2017,151:193-203.
［16］Goldstraw P,Chansky K,Crowley J,et al.The IASLC Lung Cancer Staging Project:Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer［J］.J Thorac Oncol,2016,11:39-51.
［17］Lencioni R，Llovet JM.Modified RECIST （mRECIST） assessment for hepatocellular carcinoma［J］.Semin Liver Dis，2010，30：52-60.
［18］Baerlocher MO，Nikolic B，Sze DY.Adverse event classification：clarification and validation of the society of interventional radiology specialty-specific system［J］.J Vasc Interv Radiol，2023，34：1-3.
［19］Aaronson NK，Ahmedzai S，Bergman B，et al.The European organization for research and treatment of cancer QLQ-C30：a quality-of-life instrument for use in international clinical trials in oncology［J］.J Natl Cancer Inst，1993，85：365-376.
［20］李万刚，崔静，王建军，等.术前支气管动脉灌注化疗治疗Ⅲa（N-2）期非小细胞肺癌［J］.介入放射学杂志，2015，24：160-165.
［21］黄坤林，刘玉金.肺癌介入治疗临床研究进展［J］.介入放射学杂志，2019，28：1005-1008.
［22］Fu Y，Li Y，Wei N，et al.Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer：long-term outcome and predictor of survival［J］.Radiol Med，2016，121：605-610.
［23］Zhu J，Zhang HP，Jiang S，et al.Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage Ⅲ squamous cell lung cancer［J］.Ther Adv Respir Dis，2017，11：301-309.
［24］Borghaei H，Gettinger S，Vokes E，et al.Five-year outcomes from the randomized，phase Ⅲ trials CheckMate 017 and 057：nivolumab versus docetaxel in previously treated non-small-cell lung cancer［J］.J Clin Oncol，2021，39：723-733.
［25］Bie Z，Li Y，Li B，et al.The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer［J］.Thorac Cancer，2019，10：1770-1778.
［26］Liu SY，Wu YL.Tislelizumab：an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer （NSCLC）［J］.Expert Opin Investig Drugs，2020，29：1355-1364.
［27］Zwitter M.Toxicity and quality of Life in published clinical trials for advanced lung cancer［J］.Support Care Cancer，2018，26：3453-3459.
［28］Liu XF，Lin H，Wang Q，et al.Drug-eluting bead bronchial arterial chemoembolization vs.chemotherapy in treating advanced non-small cell lung cancer：comparison of treatment efficacy，safety and quality of Life［J］.Eur Rev Med Pharmacol Sci，2021，25：2554-2566.
［29］Garon EB，Rizvi NA，Hui RN，et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.N Engl J Med，2015，372：2018-2028.
［30］Gandhi L，Rodriguez-Abreu D，Gadgeel S，et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer［J］.N Engl J Med，2018，378：2078-2092.
［31］West H，McCleod M，Hussein M，et al.Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer （IMpower130）：a multicentre，randomised，open-label，phase 3 trial［J］.Lancet Oncol，2019，20：924-937.
［32］Takayama K，Ichiki M，Matsumoto T，et al.Phase Ⅱ study on biweekly combination therapy of gemcitabine plus carboplatin for the treatment of elderly patients with advanced non-small cell lung cancer［J］.Oncologist，2020，25：208-e417.
［33］Fei QL，Zhou YY，Yuan YX，et al.An applied anatomical study of bronchial artery［J］.Surg Radiol Anat，2018，40：55-61.
［34］Yener O，Türkvatan A，Yüce G，et al.The normal anatomy and variations of the bronchial arteries：evaluation with multidetector computed tomography［J］.Can Assoc Radiol J，2015，66：44-52.
［35］Shang B，Li J，Wang X，et al.Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug-eluting beads in patients with stage Ⅱ–Ⅳ lung cancer：a prospective cohort study［J］.Thorac Cancer，2020，11：2155-2162.
［36］Fu Z，Wang C，Wei W，et al.Efficacy and safety of drug-eluting beads bronchial arterial chemoembolization versus conventional bronchial arterial chemoembolization in lung cancer patients with hemoptysis［J］.Future Oncol，2022，18：2805-2815.

相似文献/References:

[1]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(02):995.

备注/Memo

备注/Memo:
（收稿日期：2024-06-14）（本文编辑：新宇）
更新日期/Last Update: 2025-02-17